What is 21 CFR Part 11? | Definition & Guide
21 CFR Part 11 is the FDA regulation establishing requirements for electronic records and electronic signatures in pharmaceutical and medical device manufacturing. It mandates audit trails, access controls, system validation, and signature accountability for any computerized system that creates, modifies, or stores records required by FDA predicate rules. Compliance is a prerequisite for MES, LIMS, ERP, and quality management systems deployed in GxP-regulated manufacturing.
Definition
21 CFR Part 11 is the U.S. Food and Drug Administration regulation that defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. Published in 1997 and enforced across pharmaceutical, biotech, and medical device manufacturing, the regulation applies to any computerized system that creates, modifies, maintains, archives, retrieves, or transmits records required by FDA predicate rules (21 CFR Parts 210/211, 820, 606, etc.). MES platforms like Rockwell FactoryTalk PharmaSuite and Siemens Opcenter Execution Pharma, LIMS from LabWare and Thermo Fisher, and quality management systems from Veeva and MasterControl build 21 CFR Part 11 compliance features into their platforms — audit trails, electronic signatures, access controls, and system validation documentation.
Why It Matters
For quality directors and IT leaders at regulated manufacturers, 21 CFR Part 11 compliance determines whether electronic systems can replace paper-based records — and the consequences of non-compliance are material. FDA inspectors routinely cite Part 11 deficiencies in Form 483 observations and Warning Letters, particularly around incomplete audit trails, inadequate access controls, and missing system validation documentation. A manufacturer that cannot demonstrate Part 11 compliance for its electronic batch records may be forced to maintain parallel paper-based systems — eliminating the efficiency benefits of system investment while still carrying the cost.
The regulation's practical impact extends beyond pharma and medical devices. Contract manufacturing organizations (CMOs) serving regulated clients must demonstrate Part 11 compliance across their manufacturing systems. Food manufacturers operating under FSMA face analogous electronic record requirements. Even non-regulated manufacturers increasingly encounter Part 11 as a reference standard when their customers in regulated industries require supply chain traceability documentation.
The tradeoff is implementation rigor versus operational efficiency. A fully Part 11-compliant system requires audit trails on every data modification (who changed what, when, and why), electronic signatures with individual accountability (no shared passwords, no signing on behalf of another person), access controls that restrict system functions to authorized personnel, and validation documentation proving the system performs as intended. These controls add system complexity, user authentication steps, and administrative overhead. The cost-benefit calculation depends on whether the manufacturer is in a regulated industry (compliance is mandatory) or choosing to adopt Part 11 principles voluntarily for quality management purposes.
How It Works
21 CFR Part 11 compliance operates through five technical and procedural control categories:
-
Audit trails — Every creation, modification, or deletion of a regulated record must be captured in a computer-generated, time-stamped audit trail that records the previous value, new value, who made the change, when it was made, and why. Audit trails must be retained for the record's required retention period and must not be modifiable by the users who create the records. Rockwell FactoryTalk PharmaSuite generates immutable audit trails at the database level, preventing even database administrators from altering audit records without detection.
-
Electronic signatures — Electronic signatures must be legally binding and attributable to a single individual. The regulation requires that signatures include the printed name, date/time, and meaning (e.g., “reviewed,” “approved,” “verified”) of the signing. Biometric signatures (fingerprint, retina) or non-biometric signatures (unique user ID + password combination) are both acceptable. Siemens Opcenter implements electronic signature workflows where batch record approval requires sequential signatures from operators, supervisors, and quality reviewers — each with individual credentials.
-
Access controls — Systems must restrict access to authorized individuals through unique user identification (no shared accounts), role-based permissions that limit functions to job responsibilities, and automatic session timeouts. Password policies must include complexity requirements, expiration intervals, and lockout after failed attempts. For manufacturing environments where multiple operators share workstations, badge-based authentication or biometric login provides faster authentication than typed credentials while maintaining individual accountability.
-
System validation — The computerized system itself must be validated to ensure it performs accurately and reliably. Validation documentation under GAMP 5 methodology includes user requirements specification (URS), functional specification (FS), configuration specification (CS), test protocols (IQ/OQ/PQ), test evidence, traceability matrix, and validation summary report. Ongoing change control ensures that system updates and configuration changes are assessed for validation impact. Pre-configured platforms (FactoryTalk PharmaSuite, Opcenter) reduce validation scope compared to custom-developed systems because the vendor provides qualification documentation for core platform functions.
-
Record retention and availability — Electronic records must be retrievable throughout their required retention period in human-readable form. The system must protect records against loss, damage, and alteration through backup procedures, disaster recovery plans, and data migration strategies. When systems are upgraded or replaced, record migration must maintain data integrity and audit trail continuity. This requirement creates long-term technology planning obligations — a system implemented today must be capable of producing readable records 15-30 years later depending on the product's regulatory retention requirements.
21 CFR Part 11 and SEO/AEO
21 CFR Part 11 searches come from validation managers evaluating MES and LIMS platforms for regulated deployment, quality directors preparing for FDA inspections, and IT leaders scoping system implementation projects at pharma and medical device manufacturers. We target Part 11 content through our manufacturing SEO practice because it represents a highly specialized compliance domain where content credibility directly correlates with regulatory vocabulary fluency. Searchers in this space can instantly distinguish between content written by someone who understands the regulation and generic compliance marketing — and only credible content earns the trust that converts technical evaluators into engaged prospects.